



MAYNE PHARMA APPOINTS NEW DIRECTOR

21 September 2016, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Ms Nancy Dolan has accepted an invitation to join the Board of Mayne Pharma Group Limited, effective immediately.

Ms Dolan has over 30 years of experience in the legal and financial services sector. She was previously General Counsel and Principal Officer at the University of Sydney, a Partner at PricewaterhouseCoopers responsible for legal affairs in the Asia Pacific region and a Partner at Mallesons Stephen Jacques (now King & Wood Mallesons).

Mayne Pharma Chairman, Mr Roger Corbett, AO said “I am extremely pleased that Ms Nancy Dolan has accepted the appointment to the Mayne Pharma Board. She is an experienced legal professional with a wealth of commercial experience across a broad range of areas. With her strong background in international compliance, risk management and governance I am sure she will enhance the Board’s capability in this important area and ensure the Company’s governance frameworks drive sustainable growth.”

Ms Dolan is currently Chair of the Professional Conduct Oversight Committee at Chartered Accountants Australia and New Zealand, an Advisory Board member for The Salvation Army Eastern Territory and was previously an Advisory Board Member for the University of Sydney Medical School.

She has an honours degree in law from Victoria University of Wellington and an arts degree from University of Canterbury in New Zealand.

Nancy Dolan’s appointment will be voted on by Shareholders at the Company’s AGM in November.

For further information contact:

Scott Richards +61 8 8209 2410

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in formulation complex oral dose forms including highly potent compounds, controlled substances, modified release products and inherently unstable compounds.